Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
1.59
Dollar change
-0.03
Percentage change
-1.85
%
IndexRUT P/E- EPS (ttm)-1.73 Insider Own37.04% Shs Outstand82.91M Perf Week1.92%
Market Cap132.70M Forward P/E- EPS next Y-0.92 Insider Trans0.31% Shs Float52.55M Perf Month3.92%
Income-142.38M PEG- EPS next Q-0.35 Inst Own25.75% Short Float3.19% Perf Quarter77.38%
Sales4.42M P/S30.02 EPS this Y33.78% Inst Trans11.02% Short Ratio1.15 Perf Half Y51.43%
Book/sh1.79 P/B0.89 EPS next Y20.00% ROA-59.79% Short Interest1.68M Perf Year-58.38%
Cash/sh1.76 P/C0.90 EPS next 5Y- ROE-69.76% 52W Range0.60 - 4.69 Perf YTD85.10%
Dividend Est.- P/FCF- EPS past 5Y-196.75% ROI-95.79% 52W High-66.10% Beta1.27
Dividend TTM- Quick Ratio7.79 Sales past 5Y-30.43% Gross Margin26.28% 52W Low164.91% ATR (14)0.07
Dividend Ex-Date- Current Ratio7.79 EPS Y/Y TTM15.09% Oper. Margin-3317.79% RSI (14)55.81 Volatility3.31% 2.28%
Employees138 Debt/Eq0.00 Sales Y/Y TTM-92.02% Profit Margin-3223.34% Recom3.00 Target Price1.55
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q24.98% Payout- Rel Volume0.24 Prev Close1.62
Sales Surprise-70.44% EPS Surprise16.09% Sales Q/Q-99.09% EarningsMar 11 AMC Avg Volume1.46M Price1.59
SMA202.98% SMA504.69% SMA200-0.00% Trades Volume357,138 Change-1.85%
Date Action Analyst Rating Change Price Target Change
Mar-12-24Downgrade Raymond James Outperform → Mkt Perform
Feb-28-24Downgrade TD Cowen Outperform → Market Perform
Feb-27-24Downgrade Citigroup Buy → Neutral
May-03-23Initiated Citigroup Buy $6
Oct-18-22Downgrade Raymond James Strong Buy → Outperform $42 → $4
Oct-18-22Downgrade Goldman Buy → Neutral $29 → $4
Oct-17-22Downgrade Piper Sandler Overweight → Neutral
Oct-17-22Downgrade Jefferies Buy → Hold
Jul-20-22Initiated Jefferies Buy $25
Sep-13-21Upgrade Raymond James Outperform → Strong Buy $27 → $39
Mar-19-24 05:30PM
Mar-11-24 05:30PM
04:29PM
04:05PM
Mar-07-24 09:15AM
03:44PM Loading…
Feb-26-24 03:44PM
09:03AM
07:10AM
Feb-20-24 04:01PM
Jan-17-24 04:47PM
Jan-09-24 08:00AM
Nov-13-23 09:45AM
Nov-07-23 04:05PM
Nov-02-23 07:42PM
05:25PM
04:22PM Loading…
04:22PM
04:01PM
Oct-11-23 04:05PM
Sep-27-23 08:30AM
Sep-20-23 04:26AM
Aug-09-23 06:10AM
Aug-03-23 05:25PM
04:21PM
04:01PM
Jul-27-23 10:13AM
Jun-15-23 02:39PM
May-25-23 09:00AM
May-08-23 04:05PM
May-05-23 06:06AM
May-04-23 06:25PM
05:32PM Loading…
05:32PM
04:05PM
May-01-23 10:01AM
Apr-27-23 10:03AM
Apr-10-23 06:00AM
Apr-05-23 01:40PM
Mar-01-23 09:00AM
Feb-28-23 07:15PM
04:05PM
Feb-17-23 09:06AM
Jan-12-23 08:00AM
Jan-09-23 09:00AM
Jan-06-23 12:14PM
Dec-21-22 10:34AM
Dec-12-22 07:00PM
Dec-07-22 06:45PM
Nov-15-22 09:55AM
Nov-08-22 08:00AM
Nov-07-22 08:00AM
Nov-04-22 08:00AM
Nov-03-22 06:45PM
04:05PM
01:00PM
09:35AM
Oct-31-22 10:00AM
Oct-27-22 10:02AM
Oct-21-22 07:54AM
Oct-18-22 09:35AM
Oct-17-22 11:08AM
09:14AM
08:48AM
07:30AM
Oct-16-22 04:30PM
Oct-11-22 09:29AM
Sep-20-22 09:03AM
Sep-14-22 06:44AM
Sep-13-22 05:30PM
Sep-10-22 09:10AM
Sep-06-22 12:13PM
08:00AM
Aug-15-22 08:00AM
Aug-14-22 08:22AM
Aug-04-22 06:25PM
04:05PM
Aug-01-22 10:01AM
Jul-30-22 08:21AM
Jul-28-22 10:02AM
Jul-20-22 10:25AM
Jun-30-22 08:00AM
Jun-23-22 04:05PM
Jun-02-22 08:00AM
May-24-22 04:05PM
May-12-22 08:00AM
May-09-22 06:07AM
May-05-22 06:55PM
04:14PM
May-04-22 09:01AM
08:25AM
Apr-20-22 04:05PM
09:00AM
Apr-08-22 08:00AM
Mar-31-22 04:05PM
Mar-21-22 08:00AM
Mar-08-22 04:13PM
Mar-01-22 05:25PM
04:06PM
08:55AM
Feb-28-22 08:00AM
Feb-20-22 08:51AM
Feb-08-22 10:19AM
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum. The company was founded by Jin Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COLUMN GROUP L PDirectorNov 16 '23Buy0.625,8403,627949,862Nov 17 04:33 PM
COLUMN GROUP L PDirectorNov 16 '23Buy0.625,8403,627949,862Nov 17 04:30 PM
COLUMN GROUP L PDirectorNov 16 '23Buy0.625,8403,627949,862Nov 17 04:28 PM
GOEDDEL DAVID VDirectorNov 16 '23Buy0.625,8403,627949,862Nov 17 04:25 PM
GOEDDEL DAVID VDirectorNov 16 '23Buy0.621,460907134,180Nov 17 04:25 PM
COLUMN GROUP L PDirectorNov 15 '23Buy0.7116,79111,880944,022Nov 17 04:33 PM
COLUMN GROUP L PDirectorNov 15 '23Buy0.7116,79111,880944,022Nov 17 04:28 PM
COLUMN GROUP L PDirectorNov 15 '23Buy0.7116,79111,880944,022Nov 17 04:30 PM
GOEDDEL DAVID VDirectorNov 15 '23Buy0.7116,79111,880944,022Nov 17 04:25 PM
GOEDDEL DAVID VDirectorNov 15 '23Buy0.712,7201,919132,720Nov 17 04:25 PM